KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Retained Earnings (2016 - 2025)

Historic Retained Earnings for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$1.9 billion.

  • CRISPR Therapeutics AG's Retained Earnings fell 4258.19% to -$1.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.9 billion, marking a year-over-year decrease of 4258.19%. This contributed to the annual value of -$1.9 billion for FY2025, which is 4258.19% down from last year.
  • According to the latest figures from Q4 2025, CRISPR Therapeutics AG's Retained Earnings is -$1.9 billion, which was down 4258.19% from -$1.8 billion recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Retained Earnings ranged from a high of $72.5 million in Q2 2021 and a low of -$1.9 billion during Q4 2025
  • For the 5-year period, CRISPR Therapeutics AG's Retained Earnings averaged around -$968.9 million, with its median value being -$988.3 million (2023).
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Retained Earnings skyrocketed by 11937.62% in 2021, and later plummeted by 124544.61% in 2022.
  • CRISPR Therapeutics AG's Retained Earnings (Quarter) stood at -$195.9 million in 2021, then plummeted by 331.87% to -$846.1 million in 2022, then dropped by 18.16% to -$999.7 million in 2023, then crashed by 36.64% to -$1.4 billion in 2024, then tumbled by 42.58% to -$1.9 billion in 2025.
  • Its last three reported values are -$1.9 billion in Q4 2025, -$1.8 billion for Q3 2025, and -$1.7 billion during Q2 2025.